Between Scylla and Charybdis: Pharma launch strategy in the MFN era

How President Trump’s Most Favored Nation agenda is forcing pharmaceutical companies to rethink pricing, launch sequencing, and the economics of innovation. 

No healthcare policy initiative in the last two decades has had the potential to reshape the global pharmaceutical industry as profoundly as President Trump’s Most Favored Nation (MFN) agenda. From the first executive order last May, to the MFN letters over the summer, to the initial agreements in the fall and the final wave of deals through the winter and into the spring, the past year has been quite an odyssey. The journey was felt most acutely by CEOs, commercial and market access leaders, and the country affiliates now tasked with achieving local access without destroying a product’s overall revenue potential.

But MFN was never going to stop at pricing and market access. It reaches into new product planning, infrastructure…